Updated 15/02/2024

Original research

• Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CEM, Warren RB; BADBIR Study Group. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis. JAMA Dermatol. 2023 Dec 6:e234846. doi: 10.1001/jamadermatol.2023.4846.

• Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CEM; BADBIR study groups; BSTOP study groups. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2023 Dec 5:ljad481. doi: 10.1093/bjd/ljad481.

• Hughes DM, Coronado JIC, Schofield P, Yiu ZZN, Zhao SS. The predictive accuracy of cardiovascular risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the Clinical Practice Research Datalink. Rheumatology (Oxford). 2023 Nov 15:kead610. doi: 10.1093/rheumatology/kead610.

• Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JNWN, Yiu ZZN, Smith CH, Griffiths CEM; BADBIR Study Group. Characteristics of “Super-Responders” and “Super-Non-Responders” to Frist Biologic Monotherapy for Psoriasis: a Nested Case-control study. Br J Dermatol. 2023 November 9 doi: 10.1093/bjd/ljad446.

• Drucker AM, Lam M, Elsawi R, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093/bjd/ljad393.

• Chen TC, Wang TC, Yiu ZZN, Lee MS, Chen LC, Chan KA, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas (GPA). Risk of serious infection and infection mortality in patients with psoriasis: a nationwide cohort study using the Taiwan National Health Insurance claims database. J Eur Acad Dermatol Venereol. 2023 Aug 23. doi: 10.1111/jdv.19466.

• Yen H, Yen H, Huang CH, Huang IH, Hung WK, Su HJ, Tai CC, Haw WY, Flohr C, Yiu ZZN, Chi CC. Systematic review and critical appraisal of urticaria clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP). J Allergy Clin Immunol Pract. 2023 Jul 12:S2213-2198(23)00773-0.

• Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZN. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies. JAMA Dermatol. 2023 May 31. doi: 10.1001/jamadermatol.2023.1338.

• Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2023 May 25:ljad179. doi: 10.1093/bjd/ljad179.

• Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2023 Apr 5:ljad107. doi: 10.1093/bjd/ljad107.

• Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM. Drug Survival for Effectiveness and Safety of Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis: Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). JAMA Dermatol. 2022 Oct 1;158(10):1131-1141.

• Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. Br J Dermatol 2023 (in press)

• Machado PM, Schäfer M, Mahil SK, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer AC, Fautrel B, Alonso CG, Saad CGS, Griffiths CEM, Lomater C, Miceli-Richard C, Wendling D, Alpizar Rodriguez D, Wiek D, Mateus EF, Sirotich E, Soriano ER, Ribeiro FM, Omura F, Rajão Martins F, Santos H, Dau J, Barker JN, Hausmann J, Hyrich KL, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro MM, Zelaya MD, Severina MLÁ, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace ZS, Yiu ZZN, Yazdany J, Robinson PC, Smith CH. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Ann Rheum Dis. 2023 Feb 14:ard-2022-223499. doi: 10.1136/ard-2022-223499. Epub ahead of print. PMID: 36787993.

• Zhao SS, Yiu ZZN, Barton A, Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. JAMA Dermatol. 2023 Jan 25:e226051. doi: 10.1001/jamadermatol.2022.6051.

• Quirke-McFarlane S, Weinman J, Cook ES, Yiu ZZN, Dand N, Langan SM, Bechman K, Tsakok T, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Barbosa IA, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Galloway JB, Griffiths CEM, Barker JN, Norton S, Smith CH, Mahil SK; PsoProtect study group. Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. Br J Dermatol. 2022 Dec 23:ljac144. doi: 10.1093/bjd/ljac144. Epub ahead of print. PMID: 36763806.

• Al-Janabi A, Ra A, Littlewood Z, Foulkes AC, Hunter HJA, Chinoy H, Moriarty CA, Hyrich KL, Limdi JK, Yiu ZZN, Griffiths CE, Warren RB. The effect of immunomodulators on seroconversion to BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. Br J Dermatol. 2022 (in press)

• Asfour L, De Brito M, Al-Janabi A, Haw WY, Johnson A, Flohr C, Yiu ZZN. Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a systematic review of alopecia areata clinical practice guidelines. Clin Exp Dermatol. 2022 

 •Haw WY, Al-Janabi A, Arents BWM, Asfour L, Exton LS, Grindlay D, Khan SS, Manounah L, Yen H, Chi CC, van Zuuren EJ, Flohr C, Yiu ZZN. Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines. Br J Dermatol. 2021

• Yiu ZZN, Mason K, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) JAMA Dermatol. 2021 Jan 1;157(1):66-73.

• Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Brown MA, Galloway JB, Smith CH. Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. 2020 Dec 23. doi: 10.1111/bjd.19755.

• Mahil SK, Dand N, Mason KJ, Yiu ZZ, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CE, Barker JN, Smith CH; Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study. J Allergy Clin Immunol. 2020 Oct 16;S0091-6749(20)31413-5.

•Yiu ZZN, Parisi R, Lunt M, Warren RB, Griffiths CEM, Langan SM, Ashcroft DM. Risk of Hospitalisation and Death Due to Infection in People With Psoriasis: A Population-based Cohort Study Using the Clinical Practice Research Datalink. Br J Dermatol. 2021;184(1):78-86.

• Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Comparing the Efficacy and Tolerability of Biologic Therapies in Psoriasis: An Updated Network Meta-Analysis. Br J Dermatol. 2020 Oct;183(4):638-649.

• Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: A Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 2020;183(2):294-302

• Drucker AM, Ellis AG, Mashayekhi S, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Küster D, Siegels D, Schmitt J, Flohr C. Systemic immunomodulatory treatments for atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol 2020 Apr 22:e200796. 

• Yiu ZZN, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group. A Standardisation Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real World Populations in Psoriasis. Br J Dermatol 2019 Dec;181(6):1265-1271. 

• Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM. Persistence and Effectiveness of Non-Biologic Systemic Therapies for Moderate-Severe Psoriasis in Adults: a Systematic Review. Br J Dermatol 2019 Aug;181(2):256-264. 

• Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kuhl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BADBIR Study Group. Development and Validation of a Multivariable Risk Prediction Model for Serious Infection in Patients with Psoriasis Receiving Systemic Therapy. Br J Dermatol 2019 Apr;180(4):894-901. 

• Yiu ZZ, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds N, Ormerod AD, Griffiths CE, Warren RB; BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 2019;180:329-337

•Yiu ZZ, Smith CH, Ormerod A, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds N, Griffiths CE, Warren RB. Risk of serious infection associated with biologic therapies in psoriasis: A prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2018 Mar;138(3):534-541.

•Yiu ZZ, Exton LS, Jabbar-Lopez Z, Mustapa MFM, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CEM, Smith CH, Warren RB. Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2016 Aug;136(8):1584-91

• Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatol. 2018 May 1;154(5):581-588.

• Jabbar-Lopez ZK, Yiu ZZ, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. J Invest Dermatol. 2017 Dec;137(12):2644-2646

• Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CE, Ashcroft DM. Impact of Biologic Therapies on Risk of Major Adverse Cardiac Events in Patients with Psoriasis: Systematic Review and Meta-analysis of Randomised Controlled Trials. Br J Dermatol 2017 Apr;176(4):890-901 

• Warren RB*, Smith CH*, Yiu ZZ*, Ashcroft DM, Barker JN, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM, Reynolds NJ, Griffiths CE. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632-40 (*joint first authors)

• Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, Mcelhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ, Smith CH, Griffiths CE. Demographics and disease characteristics of psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2015;173(2):510-8

• Theodorakopoulou E*, Yiu ZZ*, Bundy C, Chularojanamontri L, Gittins M, Jamieson LA, Motta L, Warren RB, Griffiths CE. Early and late onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. Br J Dermatol 2016;175(5):1038-1044 (*joint first authors)

Research Letters

• Venables ZC, Gran S, Levell NJ, Yiu ZZN, Proby CM. International melanoma and non-melanoma skin cancer mortality trends - is it time to re-focus our attention? Clin Exp Dermatol. 2023 Dec 7:llad438. doi: 10.1093/ced/llad438.

• Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CM, Barker JN, Smith CH, Galloway JB, Mahil SK; PsoProtect study group. Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. Br J Dermatol. 2022 Aug;187(2):254-256.

• Yiu ZZN, Harding G, Griffiths CEM, Warren RB, McMullen E, Hunter HJA. Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study. Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20062.

• Mahil SK, Yates M, Yiu Z, Langan SM, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Norton S, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Brown MA, Galloway JB, Griffiths CM, Barker JN, Smith CH; PsoProtect study group. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e636-e640

• Al-Janabi A, Littlewood Z, Griffiths CEM, Hunter HJA, Chinoy H, Moriarty C, Yiu ZZN, Warren RB. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. Br J Dermatol 2021 May 12. doi: 10.1111/bjd.20479.

• Mahil SK, Yates M, Yiu Z, Langan SM, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Norton S, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Brown MA, Galloway JB, Griffiths CM, Barker JN, Smith CH; PsoProtect study group. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol. 2021 Jun 17. doi: 10.1111/jdv.17450. Epub ahead of print.

• Yiu ZZN, Harding G, Griffiths CEM, Warren RB, McMullen E, Hunter HJA. Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study. Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20062.

• Mahil SK*, Yiu ZZN*, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. (in press) (*joint first authors)

• Yiu ZZN, Jabbar-Lopez ZK, Ahmed S, Mohd Mustapa MF, Chi CC, Flohr C. Results from the BJD survey on readership views towards clinical practice guidelines. Br J Dermatol 2020 Feb 18. doi: 10.1111/bjd.18960.

Guidelines

• Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. Br J Dermatol. 2020 Mar 18. doi: 10.1111/bjd.19039. Online ahead of print.

• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning V, Warren RB, Exton LS, Mustapa MFM. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017 Sep;177(3):628-636

Protocols

• Drucker AM, Ellis A, Jabbar-Lopez Z, Yiu ZZN, Arents BWM, Burton T, Spuls PI, Küster D, Schmitt J, Flohr C. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. BMJ Open. 2018 Aug 29;8(8):e023061.

Meeting reports

• Yiu ZZN, Barker JNWN, Barnes MR, Di Meglio P, Emsley R, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; PSORT Consortium. Meeting Report: Psoriasis Stratification to Optimise Relevant Therapy Showcase. J Invest Dermatol. 2021 Mar 23;S0022-202X(21)01010-1. 

Editorials and Review articles

• de Brito M, Yiu ZZN. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? Am J Clin Dermatol. 2021 Jul 22. doi: 10.1007/s40257-021-00612-9. Online ahead of print.

• Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group. The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. Br J Dermatol 2020 Dec;183(6):981-983. 

•Yiu ZZN, Chi CC, Flohr C. All aboard the BJD for global dissemination of high-quality dermatology clinical practice guidelines. Br J Dermatol 2020; 183(1):3-4

•Malhi IS, Yiu ZZN. Algorithm based smartphone apps to assess risk of skin cancer in adults: critical appraisal of a systematic review. Br J Dermatol . 2020 Aug 31. doi: 10.1111/bjd.19502.

• Asfour L, Yiu ZZN, Warren RB. How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting. Expert Opin Drug Saf. 2020 Mar 21:1-9

• Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal. Br J Dermatol 2019 Jun;180(6):1348-13

• Yiu ZZ, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg 2018;37(3):143-147

• Yiu ZZN, Warren RB. Guselkumab for Psoriasis: A Critical Appraisal of Phase III Studies. Immunotherapy. 2018 Jan;10(1):67-75.

• Yiu ZZN, Warren RB. Raising standards for the evaluation of future psoriasis therapeutics: A critical checklist. Clin Pharmacol Ther. 2017 Jul 12 (in press)

• Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017;13:315-323

• Yiu ZZ, Warren RB. The Potential Utility of Tildrakizumab: an Interleukin-23 Inhibitor for the Treatment of Psoriasis. Expert Opin Investig Drugs 2017;26(2):243-249

• Yiu ZZ. Disease-Specific Treatment Registries for Research – Psoriasis as an Exemplar. Br J Dermatol 2017;176:794-796

• Yiu ZZ, Warren RB. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. Am J Clin Dermatol. 2016;17(3):191-200 

• Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol. 2015 Nov 11:1-4

• Yiu ZZ, Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy. 2015 Feb;7(2):119-33.

• Yiu ZZ, Warren RB, Mrowietz U, Griffiths CE. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat. 2014 Nov 26:1-24

• Yiu ZZ, Griffiths CE, Warren RB. Safety of biologic therapies for psoriasis on reproductive potential and outcomes in males and females. Br J Dermatol 2014 Sep;171(3):485-91

• Ali FR, Yiu ZZ, Yell J. Potassium iodide: a Dickensian drug for dermatological disease. Dermatology in practice 2015;21:7-8

• Hanley T, Handford M, Lavery D, Yiu ZZ. Assessment and monitoring of biologic drug adverse events in patients with psoriasis. Psoriasis: Targets and Therapy 2016 April;6:41-54

Case reports

• Khoo AB, Ali FR, Yiu ZZ, Ferguson J. Carbamazepine induced Stevens-Johnson Syndrome. BMJ Case Rep 2016 Mar 11;2016. pii: bcr2016214926. doi: 10.1136/bcr-2016-214926

• Ali FR, Yiu ZZ, Ogden S. Minocycline-induced pigmentation of the skin and nails. Postgrad Med J 2015 Nov;91(1081):662

• Yiu ZZ, Ali FR, Griffiths CE. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. Clin Exp Dermatol 2016;41(4):407-9 

• Ali FR, Yiu ZZ, Fitzgerald D. Inflammation of actinic keratoses during paclitaxel chemotherapy. BMJ Case Rep. 2015 Jun 8; pii: bcr2015209925. doi: 10.1136/bcr-2015-209925.

• Yiu ZZ, Madan V, Griffiths CE. Acne conglobata and adalimumab: use of tumour necrosis factor-alpha antagonists in treatment-resistant acne conglobata and review of the literature. Clin Exp Dermatol 2015;40(4):383-6

• Yiu ZZ, Ali FR, Wilson MS, Mowatt D, Lyon CC. Giant Condylomata Acuminata of Buschke and Lowenstein: A peristomal variant. Int J Surg Case Rep 2014;5:1014-1017

Health Technology Assessment

• Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN, Wittmann M. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Health Technol Assess. 2024 Jan;28(4):1-113

Editorials and Commentaries

• Yiu ZZN, Chi CC, Ingram JR, Flohr C. Checking for update…living systematic reviews and clinical practice guidelines in the BJD. Br J Dermatol. 2022 May;186(5):761-762.

• Yiu ZZN, Chi CC, Flohr C. All aboard the BJD for global dissemination of high-quality dermatology clinical practice guidelines. Br J Dermatol 2020 Jul;183(1):3-4

• Alabas OA, Yiu ZZN. A sprinkle of methotrexate to go with biologics: a safe recipe? Br J Dermatol. 2024 Jan 3:ljad505. doi: 10.1093/bjd/ljad505.

• Yiu ZZN. Repurposing existing trial data to infer relative efficacy of biologics: guselkumab vs. ustekinumab for psoriasis. Br J Dermatol 2020 Jan 14 (in press)

• Parisi R, Yiu ZZN. The worldwide epidemiology of rosacea. Br J Dermatol 2018;179(2):239-240

• Yiu ZZ. Psoriasis and increased drug utilisation: A true burden of psoriasis or potential surveillance bias of co-morbidities? Br J Dermatol 2017;176:566-567

Correspondence

• Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors. Br J Dermatol 2017 Dec;177(6):1766-1767. 

• Jabbar-Lopez ZK, Yiu ZZ, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Author Reply to: Letter to the Editor in Response to recently published article, ‘Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis’ J Invest Dermatol 2017 Dec;137(12):2644-2646. 

Book chapters

• Yiu Z, Warren R, Menter A. Introduction. In: Warren R, Menter A ed. Handbook of Psoriasis and Psoriatic Arthritis. Adis, pp.1-5